Menu
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens
➡️ A good opportunity to find out the recent achivements we made and the upcoming clinical development plan.
Click here : https://lnkd.in/eudjdypq
BIO-Europe Spring, the premier springtime partnering event takes place in Barcelona [18-20 March] and brings key biopharma actor to elevate life science partnerships.
hashtag#Biotech hashtag#Innovation hashtag#Immunotherapy hashtag#STCPlatform hashtag#collaborations